FY2028 EPS Estimates for Haemonetics Cut by Zacks Research

Key Points

• Zacks Research has reduced its FY2028 earnings per share (EPS) estimate for Haemonetics to $5.82, down from $5.83, while the current consensus estimate for the full year is $4.55.
• Haemonetics reported an EPS of $1.10 for the last quarter, exceeding expectations, but its revenue was down 4.4% year-over-year at $321.39 million.
• Several analysts have adjusted their price targets for Haemonetics, with the average price target now at $75.89 and a mix of ratings that include one Strong Buy, seven Buy, two Hold, and one Sell.

Haemonetics Corporation (NYSE:HAE - Free Report) - Equities research analysts at Zacks Research decreased their FY2028 earnings per share (EPS) estimates for shares of Haemonetics in a note issued to investors on Monday, October 6th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $5.82 per share for the year, down from their previous forecast of $5.83. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating the consensus estimate of $1.01 by $0.09. The firm had revenue of $321.39 million during the quarter, compared to analysts' expectations of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company's revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.

A number of other research analysts have also recently commented on HAE. Needham & Company LLC restated a "buy" rating and set a $68.00 price target (down previously from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Robert W. Baird initiated coverage on shares of Haemonetics in a research note on Thursday, June 26th. They set an "outperform" rating and a $87.00 price target for the company. JPMorgan Chase & Co. restated a "neutral" rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Mizuho cut their price target on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Finally, Barrington Research restated an "outperform" rating and set a $86.00 price target on shares of Haemonetics in a research note on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $75.89.

Haemonetics Stock Down 0.6%

Shares of HAE opened at $49.27 on Wednesday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 15.07, a P/E/G ratio of 0.91 and a beta of 0.37. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. Haemonetics has a 12 month low of $47.31 and a 12 month high of $94.99. The company has a 50-day moving average price of $55.16 and a two-hundred day moving average price of $63.47.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of HAE. Quarry LP raised its stake in shares of Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after acquiring an additional 192 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock valued at $33,000 after purchasing an additional 165 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock valued at $50,000 after purchasing an additional 320 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Haemonetics in the second quarter valued at approximately $64,000. Institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.